Current and potential chemotherapeutic agents used for induction chemotherapy in the treatment of breast cancer

I C Smith, A W Hutcheon, S D Heys

Research output: Contribution to journalLiterature review

10 Citations (Scopus)

Abstract

A substantial proportion of breast cancers are large (<3 cm) or locally advanced (T-3, T-4, TXN2) at the time of initial presentation. The therapeutic goals that must be achieved in patients with such cancers are to obtain adequate local disease control so that surgery can be performed and to abolish occult distant metastases therefore improving survival. Over the past three decades conventional adjuvant chemotherapy regimens have been employed pre-operatively (neo-adjuvant or primary chemotherapy) to achieve these goals. Studies have now shown that the survival of patients who receive neo-adjuvant chemotherapy is comparable to that of those who receive the same chemotherapy regimen following surgery. It is also apparent that although clinical tumour response rates to neo-adjuvant chemotherapy may be high there is considerable scope for improvement in the corresponding pathological tumour response. Furthermore, data from major studies that have comprehensively evaluated the use of pre-operative chemotherapy now indicates that the pathological response of breast cancers following treatment is of far greater prognostic importance than the clinical response. Recent interests has focoused, therefore, on the implementation of more prolonged or dose intensive chemotherapy regimens with the aims of improving pathological response to treatment and ultimately overall survival. Newer antineoplastic agents are also becoming available that may be used alone or in combination with conventional therapies in order that tumor response may be improved. This review describes current and potential therapeutic agents that may be used for the induction therapy of breast cancer.

Original languageEnglish
Pages (from-to)327-343
Number of pages17
JournalCurrent Pharmaceutical Design
Volume6
Publication statusPublished - 2000

Keywords

  • RAT MAMMARY-CARCINOMA
  • HEALTHY POSTMENOPAUSAL WOMEN
  • BONE-MINERAL DENSITY
  • GROWTH-FACTOR-BETA
  • ESTROGEN-RECEPTOR
  • AROMATASE INHIBITOR
  • HODGKINS-DISEASE
  • ADJUVANT THERAPY
  • OVARIAN-CANCER
  • PHASE-III

Cite this

Current and potential chemotherapeutic agents used for induction chemotherapy in the treatment of breast cancer. / Smith, I C ; Hutcheon, A W ; Heys, S D .

In: Current Pharmaceutical Design, Vol. 6, 2000, p. 327-343.

Research output: Contribution to journalLiterature review

@article{43296a7cb77c46bc9b8aa3b7bdfdf91b,
title = "Current and potential chemotherapeutic agents used for induction chemotherapy in the treatment of breast cancer",
abstract = "A substantial proportion of breast cancers are large (<3 cm) or locally advanced (T-3, T-4, TXN2) at the time of initial presentation. The therapeutic goals that must be achieved in patients with such cancers are to obtain adequate local disease control so that surgery can be performed and to abolish occult distant metastases therefore improving survival. Over the past three decades conventional adjuvant chemotherapy regimens have been employed pre-operatively (neo-adjuvant or primary chemotherapy) to achieve these goals. Studies have now shown that the survival of patients who receive neo-adjuvant chemotherapy is comparable to that of those who receive the same chemotherapy regimen following surgery. It is also apparent that although clinical tumour response rates to neo-adjuvant chemotherapy may be high there is considerable scope for improvement in the corresponding pathological tumour response. Furthermore, data from major studies that have comprehensively evaluated the use of pre-operative chemotherapy now indicates that the pathological response of breast cancers following treatment is of far greater prognostic importance than the clinical response. Recent interests has focoused, therefore, on the implementation of more prolonged or dose intensive chemotherapy regimens with the aims of improving pathological response to treatment and ultimately overall survival. Newer antineoplastic agents are also becoming available that may be used alone or in combination with conventional therapies in order that tumor response may be improved. This review describes current and potential therapeutic agents that may be used for the induction therapy of breast cancer.",
keywords = "RAT MAMMARY-CARCINOMA, HEALTHY POSTMENOPAUSAL WOMEN, BONE-MINERAL DENSITY, GROWTH-FACTOR-BETA, ESTROGEN-RECEPTOR, AROMATASE INHIBITOR, HODGKINS-DISEASE, ADJUVANT THERAPY, OVARIAN-CANCER, PHASE-III",
author = "Smith, {I C} and Hutcheon, {A W} and Heys, {S D}",
year = "2000",
language = "English",
volume = "6",
pages = "327--343",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",

}

TY - JOUR

T1 - Current and potential chemotherapeutic agents used for induction chemotherapy in the treatment of breast cancer

AU - Smith, I C

AU - Hutcheon, A W

AU - Heys, S D

PY - 2000

Y1 - 2000

N2 - A substantial proportion of breast cancers are large (<3 cm) or locally advanced (T-3, T-4, TXN2) at the time of initial presentation. The therapeutic goals that must be achieved in patients with such cancers are to obtain adequate local disease control so that surgery can be performed and to abolish occult distant metastases therefore improving survival. Over the past three decades conventional adjuvant chemotherapy regimens have been employed pre-operatively (neo-adjuvant or primary chemotherapy) to achieve these goals. Studies have now shown that the survival of patients who receive neo-adjuvant chemotherapy is comparable to that of those who receive the same chemotherapy regimen following surgery. It is also apparent that although clinical tumour response rates to neo-adjuvant chemotherapy may be high there is considerable scope for improvement in the corresponding pathological tumour response. Furthermore, data from major studies that have comprehensively evaluated the use of pre-operative chemotherapy now indicates that the pathological response of breast cancers following treatment is of far greater prognostic importance than the clinical response. Recent interests has focoused, therefore, on the implementation of more prolonged or dose intensive chemotherapy regimens with the aims of improving pathological response to treatment and ultimately overall survival. Newer antineoplastic agents are also becoming available that may be used alone or in combination with conventional therapies in order that tumor response may be improved. This review describes current and potential therapeutic agents that may be used for the induction therapy of breast cancer.

AB - A substantial proportion of breast cancers are large (<3 cm) or locally advanced (T-3, T-4, TXN2) at the time of initial presentation. The therapeutic goals that must be achieved in patients with such cancers are to obtain adequate local disease control so that surgery can be performed and to abolish occult distant metastases therefore improving survival. Over the past three decades conventional adjuvant chemotherapy regimens have been employed pre-operatively (neo-adjuvant or primary chemotherapy) to achieve these goals. Studies have now shown that the survival of patients who receive neo-adjuvant chemotherapy is comparable to that of those who receive the same chemotherapy regimen following surgery. It is also apparent that although clinical tumour response rates to neo-adjuvant chemotherapy may be high there is considerable scope for improvement in the corresponding pathological tumour response. Furthermore, data from major studies that have comprehensively evaluated the use of pre-operative chemotherapy now indicates that the pathological response of breast cancers following treatment is of far greater prognostic importance than the clinical response. Recent interests has focoused, therefore, on the implementation of more prolonged or dose intensive chemotherapy regimens with the aims of improving pathological response to treatment and ultimately overall survival. Newer antineoplastic agents are also becoming available that may be used alone or in combination with conventional therapies in order that tumor response may be improved. This review describes current and potential therapeutic agents that may be used for the induction therapy of breast cancer.

KW - RAT MAMMARY-CARCINOMA

KW - HEALTHY POSTMENOPAUSAL WOMEN

KW - BONE-MINERAL DENSITY

KW - GROWTH-FACTOR-BETA

KW - ESTROGEN-RECEPTOR

KW - AROMATASE INHIBITOR

KW - HODGKINS-DISEASE

KW - ADJUVANT THERAPY

KW - OVARIAN-CANCER

KW - PHASE-III

M3 - Literature review

VL - 6

SP - 327

EP - 343

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

ER -